A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Part of paid clinical trials in Fresno, California.

Sponsor
Eli Lilly and Company
Study ID
NCT03724981
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.

Key Dates

Start date
Oct 18, 2018
Status verified
Aug 2019
Primary completion
Apr 12, 2019
Completion
Apr 12, 2019

Study Design

Enrollment
312 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Experimental: Dulaglutide Pen
    Injection of commercial dulaglutide pen on a practice pad.
  • Experimental: Semaglutide Pen
    Injection of commercial semaglutide pen on a practice pad.

Primary Outcome Measure

Participant Preference Between 2 Injection Devices Based on Global Preference Item [ Time Frame: Day 1 ]

Locations (14)

FacilityCityStateZIPSite coordinators
Valley ResearchFresnoCalifornia93720-
Long Beach Center for Clinical ResearchLong BeachCalifornia90807-
Palm Harbor Medical AssociatesPalm HarborFlorida34684-
Georgia Clinical ResearchSnellvilleGeorgia30078-
Cedar-Crosse Research CenterChicagoIllinois60607-
L-Marc Research CenterLouisvilleKentucky40213-
EvideraBethesdaMaryland20814-
Carolina Research Center, Inc.ShelbyNorth Carolina28150-
Lillestol Research LLCFargoNorth Dakota58104-
BRCR Medical Center, Inc.Camp HillPennsylvania17011-
Juno ResearchHoustonTexas77040-
Juno Research, LLCHoustonTexas77054-
PI-Coor Clinical Research, LLCAnnandaleVirginia22003-
Manassas Clinical Research CenterManassasVirginia20110-

Find similar trials in Fresno, CA

By condition

Related Studies